1. Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors.
- Author
-
Shibasaki, Ikuko, Nakajima, Toshiaki, Fukuda, Taira, Hasegawa, Takaaki, Ogawa, Hironaga, Tsuchiya, Go, Takei, Yusuke, Tezuka, Masahiro, Kato, Takashi, Kanazawa, Yuta, Kano, Yasuyuki, Kuwata, Toshiyuki, Ouchi, Motoshi, Toyoda, Shigeru, Aso, Yoshimasa, and Fukuda, Hirotsugu
- Subjects
- *
CD26 antigen , *ADIPOKINES , *CARDIOVASCULAR surgery , *ADIPOSE tissues , *ATRIAL fibrillation , *CAROTID intima-media thickness , *BLOOD sugar - Abstract
Dipeptidyl peptidase 4 (DPP-4) is a novel adipokine and may be involved in the association between adipose tissue and metabolic syndrome. We investigated DPP-4 and adiponectin levels in the serum, subcutaneous adipose tissue (SAT), and epicardial adipose tissue (EAT), and their relationship with preoperative factors, as well as comparing the DPP-4 levels in SAT and EAT with and without DPP-4 inhibitors. This study included 40 patients (25 men, age 67.5 ± 13.8 years). The serum adipokine, DPP-4, and adiponectin levels in SAT and EAT were measured using ELISA and Western blotting. The DPP-4 and adiponectin levels were significantly higher in the SAT than in the EAT. The serum DPP-4 and DPP-4 activity levels had no correlation with the DPP-4 levels in the SAT and EAT, but the DPP-4 levels in the SAT and EAT had a positive correlation. The DPP-4 levels in the SAT were positively correlated with atherosclerosis, diabetes mellitus, DPP-4-inhibitor use, and fasting blood glucose. The DPP-4 levels in the EAT showed a negative correlation with eGFR and a positive correlation with atrial fibrillation. The DPP-4 activity in the serum had a lower tendency in the group taking DPP-4 inhibitors than in the group not taking them. DPP-4 inhibitors may suppress angiogenesis and adipose-tissue hypertrophy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF